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Background: Prostate cancer is the most common cancer among men in many countries. The aim of the present
study was to find out how the symptoms leading to a diagnosis, diagnostic procedures and stages of the disease
among prostate cancer patients have changed over a period of 20 years.
Methods: This retrospective chart review consisted of 421 prostate cancer patients whose treatment was started in
the years 1982, 1987, 1992, 1997 and 2002 at the Oulu University Hospital. Earlier prostatic disorders, specific
urological symptoms, diagnostic procedures, the TNM classification and histological grade were recorded.
Results: The number of symptom-free prostate cancer patients increased over the 20 years, as did the number of
men suffering from chronic prostatitis, although the latter increase was not statistically significant. A drop in the
number of clinical T4 cases and increase of clinical T1 and clinical T2 cases was recorded but no clear change in the
histological distribution occurred. The 5-year prostate cancer-specific survival improved significantly over the 20
years. The urologist was found to be the person who was contacted first most often.
Conclusions: Our data indicate that the number of prostate cancer patients has increased hugely over the period
from 1982 to 2002 and although the clinical T stage has moved towards earlier stages, the proportion of well
differentiated cancers remains low, so that most patients have clinically significant cancer with the need of some
form of therapy. Further, prostate cancer-specific survival improved significantly over the period.
Keywords: Prostate cancer, Symptoms, Diagnostics, Chronic prostatitisBackground
Prostate cancer incidence is continuously increasing
among men, a trend that can be explained mostly by
better diagnostic procedures and the increase in life ex-
pectancy for men [1-4]. Despite the huge efforts aimed
at prostate cancer research, the prostate-specific antigen
(PSA) still remains the main indicator for asymptomatic
or mildly symptomatic prostate cancer detection [5].
The aim of the current study was to evaluate how the
symptoms leading to prostate cancer diagnosis and the
diagnostic procedures used have evolved in Northern* Correspondence: markku.vaarala@oulu.fi
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reproduction in any medium, provided the orFinland over a period of 20 years and what effects these
changes have brought with them. This period was selected
mainly to evaluate the impact of PSA testing on these
diagnostic and clinical aspects, as the early years reflect
the pre-PSA era and the PSA test has been available in
Finland since 1992.Methods
The investigation was retrospective and was based on
the review of charts from prostate cancer patients at
Oulu University Hospital, whose treatment was started
in the years 1982, 1987, 1992, 1997 and 2002. The refer-
ence area was served by one university hospital and four
central hospitals which have employed at least one ur-
ologist since 1982. The total area comprised 724,600 in-
habitants, of whom 378,700 live in the primary area ofral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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have remained quite stable since 1982. Most of the treat-
ments provided in this reference area were not initiated
at the university hospital but at the central and regional
hospitals. Only patients who were thought to be candi-
dates for radical therapy were referred directly to the
university hospital for evaluation. The register of the
hospital was searched for patients treated for prostate
cancer in the urological department or those who visited
the outpatient department in the years in question. This
search yielded a total of 421 patients. The research plan
was approved by the Ethics Council of the Oulu Univer-
sity Hospital.
Patient chart review
The following data were collected during patient chart re-
view: all data on the patients’ diagnoses from the patient
charts, focusing on earlier prostatic disorders (such as
prostatitis and hyperplasia), specific urological symptoms
before the first visit to the hospital, such as sexually trans-
mitted diseases, urinary tract infections, dysuria of any
kind, haematuria, pain/discomfort and haematospermia,
and laboratory results obtained before or at the first visit
to the hospital (serum acid phosphatase concentration,
serum prostatic acid phosphatase concentration, serum
PSA concentration, alkaline phosphatase concentration,
haemoglobin value and creatinine value). Other notable
symptoms such as bone pain, pathological fractures, an-
aemia, paraplegia, urinary retention and uraemia were also
recorded. Diagnostic procedures performed outside the
hospital (such as digital rectal examination (DRE), cy-
tology, biopsy, serum acid phosphatase concentration,
serum prostatic acid phosphatase concentration, serum
PSA concentration, alkaline phosphatase concentration
values) and at Oulu University Hospital (laboratory tests,
transrectal ultrasonography (TRUS), cytology, biopsy,
bone scan, X-ray, computed tomography (CT), magnetic
resonance imaging (MRI), diagnostic transurethral resec-
tion of prostate (TURP), date of diagnosis, urinary flow
rate and volume of residual urine) were ascertained separ-
ately. Symptoms, history of urological diseases and diagnos-
tic findings in the laboratory and radiological examinations
were encoded as ‘yes/positive’ or ‘no/negative’. Group ‘yes/
positive’ contains cases with the stated specific symptoms
or history of urological diseases, and cases with finding
supporting prostate cancer diagnosis in the laboratory or
radiological examinations. All other cases were break down
on ‘no/negative’. We were also interested in the status of
the first person to be contacted. The TNM classification [6]
and histological findings were taken as part of the diagnosis.
The TNM classification took the form of a pathological es-
timate if the patient had undergone radical prostatectomy,
and in other cases it was just a clinical estimate. A histo-
logical grading into three World Health Organizationclasses (well, moderately and poorly differentiated) was
used throughout almost the entire period concerned, except
in 2002, when all patients were graded according to the
Gleason classification. These latter findings were therefore
transformed on the assumption that Gleason scores 2 to 4
are identical to well differentiated adenocarcinoma of the
prostate, 5 to 7 to moderately differentiated, and 8 to 10 to
poorly differentiated.
Statistical analyses
Data were analysed using the SPSS program (SPSS Inc.,
Chicago, IL, USA). Comparison between treatment
years was done for categorical data using the Chi-
Square linear-by-linear association test. Continuous var-
iables were analysed by analysis of variance (ANOVA)
or by the Kruskal-Wallis non-parametric test. Two-
tailed P values are reported. Prostate-cancer-specific
survival rates were calculated using the Kaplan-Meier
method, and the statistical significance between groups
was analysed using the log-rank test.
Results
There was a trend toward diagnosis at younger age during
the period. Mean age of prostate cancer patients whose
treatment was started in the years 1982, 1987, 1992, 1997
and 2002 was 70.5 years (range 54–87 years), 70.8 years
(49–88 years), 71.2 years (54–88 years), 69.6 years (48–91
years) and 67 years (40–91 years), respectively. The propor-
tion of patients contacting a urologist directly increased, as
did the proportion contacting a general practitioner (GP)
(Table 1). There was some change in the symptoms that
the patients had described before the diagnosis of prostate
cancer (Table 2), with the proportion with dysuria or urin-
ary retention of any kind decreasing during the given
period (P=0.003 for dysuria and <0.001 for urinary reten-
tion). Very few patients presented with bone pain. Symp-
toms and signs such as haematuria, pain/discomfort and
haematospermia, paraplegia, pathological fractures and an-
aemia were also investigated, but the prevalence of these
remained stable over the 20 years (data not shown).
The number of patients with the history of urinary
tract infection, prostatitis/chronic pelvic pain and pros-
tatic hyperplasia is shown in Table 3. The number of pa-
tients with the history of benign prostatic hyperplasia
increased but not significantly (P=0.9). The number of
patients with sexually transmitted diseases was very low
as there was only one patient in 1987 and in 1992 with
the known history of sexually transmitted diseases.
Diagnostic procedures performed outside the hospital
that led to a suspicion or diagnosis of prostate cancer
are detailed in Figure 1. The suspicion of prostate cancer
had been aroused by a DRE in 33 (75%) out of the 44
patients diagnosed in 1982, but in 70 (43.2%) of the total
of 162 patients in 2002. The rest of the patients had no
Table 1 The first person to be contacted leading to a prostate cancer diagnosis
First contact person 1982 1987 1992 1997 2002 Total
GP
n (%) 20 (48.8) 18 (46.2) 28 (53.8) 75 (64.1) 87 (55.4) 228 (56.2)
Specialist/surgeon
n (%) 16 (39.0) 18 (46.2) 18 (34.6) 29 (24.8) 29 (12.1) 100 (24.6)
Urologist
n (%) 3 (7.3) 2 (5.1) 5 (9.6) 11 (9.4) 38 (24.2) 59 (14.5)
Other
n (%) 2 (4.9) 1 (2.6) 1 (1.9) 2 (1.7) 13 (8.3) 19 (4.7)
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whether they were examined or not. The proportion of
positive prostate biopsies taken outside the hospital in-
creased from 6.8% in 1982 to 24.7% in 2002, and the pro-
portion of patients with no symptoms and/or screened
cases with elevated laboratory values increased from 4.5%
to 86.4%. The number (the percentage of cases diagnosed
each year) of asymptomatic patients with elevated PSA
value was nine (17.3%), 93 (77.5%) and 140 (86.4%) in
1992, 1997 and 2002, respectively (P <0.001).
Since prostatic cytology was replaced by histology as a
diagnostic method in the course of the period concerned, a
cytological sample was taken from only one (0.6%) patient
in 2002, while 24 (54.5%) patients were examined in this
manner in 1982. Conversely, where only one (2.3%) patient
underwent TRUS in 1982, the figure was 25 (58.1%) in
1987, 39 (75%) in 1992, 106 (88.3%) in 1997 and 132
(81.5%) in 2002. The use of X-ray examinations for the
diagnosis of prostate cancer decreased over the same
period, and CT scans and MRI were very seldom used. The
number of diagnostic TURPs decreased from 15 (34.1%)
out of a total of 44 patients in 1982 to 13 (8%) out of 162
patients in 2002.
The distribution of clinical T classifications (TNM
classification) is presented in Figure 2. There was a clear
decrease in the number of clinical T4 cases, whereasTable 2 Symptoms before the diagnosis of prostate cancer
Symptoms 1982 1987 1
Dysuria
Yes n (%) 29 (65.9) 28 (65.1) 31
No n (%) 15 (34.1) 15 (34.9) 21
Bone pain
Yes n (%) 4 (9.1) 1 (2.3) 3
No n (%) 40 (90.9) 42 (97.7) 49
Urinary retention
Yes n (%) 11 (25.0) 9 (20.9) 13
No n (%) 33 (75) 34 (79.1) 39clinical T1 and clinical T2 cases increased significantly
during the period (P= 0.001).
The trend in histological grading is illustrated in
Figure 3. Moderately differentiated cancers were always
the most common, while the proportion of well differen-
tiated cancers was highest in 1997.
The 5-year prostate-cancer-specific survival improved
during the period (Figure 4, P <0.001). Half of the patients
and only 4.4% of the patients whose treatment was started
in 1982 and 2002, respectively, died of prostate cancer
within 5 years.
Discussion
In this retrospective chart review, we evaluated the symp-
toms and diagnostic procedures leading to prostate cancer
diagnosis in Northern Finland over a period of 20 years.
The results point to a clear change in the diagnosis and
symptoms of prostate cancer patients over the period.
Where 75.6% of the patients in 1982 were diagnosed or a
suspicion of prostate cancer was aroused on the basis of
DRE, the most frequent finding leading to prostate cancer
diagnosis in 1997 was already the PSA test (elevated value
in 77.5%). It also appears that GPs may not have
performed DRE on all patients. The question therefore
arises: do we need DRE at all anymore? Philip et al. [7],
who studied whether a DRE is necessary for the diagnosis992 1997 2002 Total
(59.6) 67 (55.8) 75 (46.3) 230 (54.6)
(40.4) 53 (44.2) 87 (53.7) 191 (45.4)
(5.8) 5 (4.2) 3 (1.9) 16 (3.8)
(94.2) 115 (95.8) 159 (98.1) 405 (96.2)
(25) 6 (5) 10 (6.2) 49 (11.6)
(75) 114 (95) 152 (93.8) 372 (88.4)
Table 3 History of specific urological symptoms before the diagnosis of prostate cancer
Symptom 1982 1987 1992 1997 2002 Total
Urinary tract infection
Yes n (%) 4 (9.1) 9 (20.9) 5 (9.6) 12 (10.0) 11 (6.8) 41 (9.7)
No n (%) 40 (90.9) 34 (79.1) 47 (90.4) 108 (90.0) 151 (93.2) 380 (90.3)
Prostatitis/chronic pelvic pain syndrome
Yes n (%) 3 (6.8) 1 (2.3) 5 (9.6) 15 (12.5) 23 (14.2) 47 (11.2)
No n (%) 41 (93.2) 42 (97.7) 47 (90.4) 105 (87.5) 139 (85.8) 374 (88.8)
Benign prostatic hyperplasia
Yes n (%) 13 (29.5) 18 (41.9) 30 (57.7) 56 (46.7) 61 (37.7) 178 (42.3)
No n (%) 31 (70.5) 25 (58.1) 22 (42.3) 64 (53.3) 101 (62.3) 243 (57.7)
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relation between DRE, biopsy findings and pathological
staging, and decided that a DRE may not be essential for
patients with a PSA level of 2.5-10 ng/mL. However, a re-
cent report clearly indicates the benefit of DRE in the de-
tection of high risk prostate cancer among men with low
PSA [8]. Currently, DRE is essential for the diagnostic pro-
cedures associated with prostate cancer [5] despite the fact
that prostate cancer diagnostic procedures are due to PSA
screening in most cases [9]. DRE, PSA, TRUS and biopsy
are the methods that are recommended [5]. A bone scan
is also an important diagnostic tool, but should only be
used for cases with a high risk of bone metastases [5].
The proportion of patients with dysuria of any kind di-
minished from 65.9% to 46.3% during the period (Table 2).
These results may be explained mostly by that fact that
cancers were detected earlier, so such symptoms did not
have time to appear. Barrett and Hamilton [10], in their
study of the symptoms of prostate cancer, noted that 70%
of the prostate cancer patients in Devon, UK, between the
years of 1998 and 2002 had lower urinary tract symptomsFigure 1 Diagnostic procedures performed outside the
hospital. DRE: digital rectal examination. No symptoms or screened
case: diagnostic examinations performed due to elevated serum acid
phosphatase concentration, serum prostatic acid phosphatase
concentration or prostate-specific antigen concentration. The
numbers above the bars indicate the percentage of patients with
specified diagnostic procedures among prostate cancer patients for
each respective year.(LUTS) and that PSA testing had been performed by a GP
in 60% of these cases; in contrast, 10% had undergone
their first PSA test performed by a urologist. Only 18% of
the asymptomatic cancers had been diagnosed by PSA
screening. After all, many patients still suffer from overt
symptoms, sometimes because of benign prostatic hyper-
plasia (BPH), which is associated with LUTS. BPH is com-
mon among men generally and is also found in many
prostate cancer patients, even though it is not considered
a premalignant lesion or precursor of carcinoma [11]. Our
results indicate that urologists are playing an increasing
role as the first people contacted by prostate cancer pa-
tients in Northern Finland, but that GPs are still most com-
monly contacted first. These changes in the availability of
healthcare providers partly explain the differences of the
first contact person presented in Table 1. In 2002 there
were more urologists working in the private sector, mean-
ing that men willing to pay for the examinations were able
to contact a urologist directly, while a patient needed a re-
ferral from the GP to a urologist during earlier years. More-
over, before PSA testing, the main reason for diagnosticFigure 2 Clinical T classification (TNM classification) of prostate
cancer patients diagnosed throughout the period. The numbers
above the bars indicate the percentage of patients with specified
clinical T class among prostate cancer patients for each respective
year. Number of diagnosed cases each year is shown (n) above the
year of diagnosis.
Figure 3 Histological grade of prostate cancer patient
diagnosed throughout the period. The numbers above the bars
indicate the percentage of patients with specified tumour grade
among prostate cancer patients at respective year. Number of
diagnosed cases each year with grade data available is shown (n)
above the year of diagnosis.
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high proportion of patients first contacting a specialist/
surgeon (Table 1).
Prostatitis and its relationship to prostate cancer have
been investigated quite intensively, without definitive con-
clusions. Some authors have reported a positive associ-
ation between prostatitis and prostate cancer [12-14], and
it has been proposed that inflammation may even lead to
prostate cancer [15]. We found here that prostatitis in-
creased among prostate cancer patients, being present in
6.8% of cases in 1982, only 2.3% in 1987, but as many as
14.2% in 2002. However, this result was not statisticallyFigure 4 The 5-year prostate cancer-specific survival of
prostate cancer patients with different treatment start year. The
prostate-cancer-specific survival improved significantly (P <0.001)
depending on the treatment start year.significant due to the small number of patients. The rise
might be explained by the fact that prostatitis has become
better known and diagnosed. Mehik and colleagues [16]
showed that the occurrence of prostatitis symptoms in
men living in Northern Finland is higher than that
reported in many other parts of the world, as the preva-
lence figure of 14.2% is well above the reported range
of 6-10%. They suggest that one cause may be the cold
climate, and estimate that the prevalence might be even
higher, as there were a considerable number of men
who were uncertain about their symptoms. It is quite
interesting, however, that the prevalence is exactly the
same as the proportion of prostate cancer patients hav-
ing prostatitis in 2002 in the present survey. This
means that prostatitis seems to be no more common
among prostate cancer patients than in the population
in general. It should also be noted that acute prostatitis
essentially raises the PSA level in serum, which can be
lowered again by treatments such as anti-inflammatory
medication and antibiotics [14,17,18]. This low PSA
after treatment does not mean, however, that the indi-
vidual does not have prostate cancer. Thompson et al.
noted a 15.2% prevalence of prostate cancer in men
with normal DRE findings and PSA levels of <4.0 ng/
mL [19].
The number of prostate cancer patients has increased
hugely over the 20 years in question. At the same time,
diagnostic procedures and the characteristics of disease
were found to have changed, as can be seen in the
present findings. Analysis of the clinical T classifications
(Figure 2) on a year-by-year basis shows that the dom-
inant classes up to 1992 were cT3 and cT4, whereas
cT2 and cT3 were clearly dominant in 1997 and cT2
alone in 2002. cT1 tumours increased between 1997
and 2002, and a similar effect has been noted in a Swed-
ish study, where Varenhorst and colleagues found that
the proportion of cT1c tumours increased from 14% to
28% between 1998 and 2002 [20]. All of these changes
are probably attributable to the PSA test and an in-
crease in general knowledge of the disease [21]. The in-
crease in the proportion of early stage tumors is the
most likely explanation for the significant improvement
of prostate-cancer-specific survival detected (Figure 4).
Some interesting findings regarding histological
changes in prostate cancer patients have also been
reported. Comparing the years 1991 and 2001 in a Scot-
tish series [22], the proportion of patients with Gleason
score 5 to 7 cancers was found to have increased, while
that of Gleason score 2 to 4 cases decreased. A similar
result was obtained in New Mexico, where Gilliand
et al. [23] noted that the proportions of Gleason score
5, 6 and 7 tumours increased with time, while those of
well differentiated tumours (2, 3 and 4) and poorly dif-
ferentiated tumours (8, 9 and10) decreased. These
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low-grade cancers may have increased along with better
diagnostic procedures and earlier diagnosis. It was also
the case in the present study that poorly and moder-
ately differentiated cancers were quite common in 2002
(21.2% and 59.6%, respectively) and that no clear
change relative to the era before PSA could be seen.
There is a bias in this part of our study, however, in that
our histological results are partly based on biopsies and
partly on prostatectomies, with the results based on bi-
opsy probably not being as reliable.
The present study has several limitations. In a retro-
spective chart review the availability and quality of the
data are limited. In patient charts, specific symptoms
may be recorded if they are present, but the absence of
recorded sign or symptom does not exclude it which
is possible to discriminate in prospective setting. Fur-
ther, although prostate cancer cases were extensively
searched based on diagnosis numbers and codes, some
cases may be missed due to wrong encoding, which
may reflect in the results. The small number of pa-
tients especially during early years of the study may
limit the ability to detect significant trends.
Conclusions
There was a clear change in the diagnosis and symptoms
of prostate cancer patients in Northern Finland over the
20-year period examined here. PSA testing is likely to be
the main explanatory factor for this change. The clinical T
class results suggest that prostate cancer may have be-
come a milder disease, but the histological grading does
not support such a conclusion. However, 5-year prostate-
cancer-specific survival improved significantly over the 20
years under examination.
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